An outbreak of New Delhi metallo-β-lactamase (NDM)--producing *Enterobacterales* was recently documented in the northwestern area of Tuscany \[[@CIT0001]\]. From November 2018 to May 2019, colonization or infection by NDM-producing *Enterobacterales* was documented in 350 patients from 9 different hospitals \[[@CIT0001]\]. We retrospectively reviewed the clinical and microbiological characteristics of 40 patients with documented bloodstream infection (BSI).

METHODS {#s1}
=======

Cases of NDM-producing BSI were identified by reviewing records from the microbiology laboratories of all 9 institutions. Demographics, clinical and laboratory findings, comorbid conditions, source of infection, source control data, treatment regimens, and 30-day mortality rates were collected from clinical charts. Source of infection and source control were defined as previously described \[[@CIT0002]\]. Septic shock was defined according to the Sepsis-3 definition \[[@CIT0003]\]. The study was approved by the local ethical committee.

Blood isolate identification and susceptibility testing were performed by matrix-assisted laser desorption ionization--time of flight mass spectrometry (MALDI-ToF MS; Vitek MS, bioMérieux; or MALDI Biotyper, Bruker Daltonics). Carbapenemase determinants were evaluated by either the Allplex Entero-DR Assay (Seegene) or RESIST-3 O.K.N. ICT immunocromatographic assay (Coris BioConcept, Gembloux, Belgium) and confirmed by real-time polymerase chain reaction as previously described \[[@CIT0004]\]. Antimicrobial susceptibility testing was carried out with reference broth microdilution, except agar dilution for fosfomycin, according to the ISO 20776-1:2006 guidelines \[[@CIT0005]\], and interpreted according to the EUCAST clinical breakpoints (v.9.0 2019; http://[www.eucast.org/clinical_breakpoints/](http://www.eucast.org/clinical_breakpoints/)).

Isolates were subjected to whole-genome sequencing (WGS) with an Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA) and a paired-end approach (2 × 300 bp). Raw sequences were assembled using SPAdes software \[[@CIT0006]\]. In silico analyses using draft-assembled genomes were performed by dedicated tools available at http://[www.genomicepidemiology.org/](http://www.genomicepidemiology.org/) (eg, MLST v.2.0) and by the BLAST suite (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>).

Continuous variables were reported as medians and interquartile ranges (IQRs). The Mann‑Whitney *U* test was used to analyze non--normally distributed data. Categorical data were expressed as frequency distributions, and the chi-square test or Fisher exact test was used to determine if differences existed between groups. Factors influencing 30-day survival were examined by univariate analysis. All significant variables at univariate analyses (*P* \< .05) were considered for the multivariate model. Hazard ratios (HRs) and 95% confidence intervals (95% CI) were calculated. Statistical significance was established at *P* ≤ .05.

RESULTS {#s2}
=======

Overall, during the study period, 47 patients with BSI caused by NDM-producing strains were initially identified in 9 hospitals in the northwestern area of Tuscany (Italy). Of these, 44 patients had a confirmed BSI caused by an NDM-producing strain, whereas 3 patients had an infection caused by strains with a different mechanism of carbapenem resistance (these cases were excluded from further analysis); the data of 4 patients were unavailable. Thus, the final cohort included 40 patients, while 35 strains were available for full microbiological and molecular characterization.

The isolates from bacteremia were identified as *Klebsiella pneumoniae* (31 patients) and *Escherichia coli* (4 patients). Preliminary characterization by WGS revealed that most *K. pneumoniae* isolates belonged to the same clonal lineage, namely sequence type (ST) 147 (n = 30, 96.8%), with a singleton of ST307. The *E. coli* isolates belonged to 2 different clonal lineages, ST8 (n = 2) and ST2 (n = 2). Among the *K. pneumoniae* isolates, all those of ST147 carried the *bla*~NDM-1~ gene, whereas those of ST307 carried *bla*~NDM-5~ (as did the 4 *E. coli* isolates). All *K. pneumoniae* isolates and the 2 ST8 *E. coli* additionally carried the *bla*~CTX-M-15~ extended-spectrum β-lactamase (ESBL) gene. A clonal analysis, based on single nucleotide polymorphisms (SNPs) evaluated on the core genome, revealed that all the ST147 isolates were closely related to each other (SNP range, 0--25), strongly suggesting that the outbreak was due to clonal expansion of a single NDM-1-producing *K. pneumoniae* strain.

Susceptibility patterns determined in vitro for the 35 characterized isolates are detailed in [Table 1](#T1){ref-type="table"}. All *K. pneumoniae* strains (n = 31) were resistant to expanded-spectrum cephalosporins, carbapenems, and β-lactamase inhibitor combinations, while they were susceptible to aztreonam (ATM)-avibactam (AVI; MIC ≤ 1 mg/L). The *E. coli* isolates (n = 4) showed a similar broad spectrum of β-lactam resistance, but they were more frequently resistant to ATM-AVI, with some differences between the ST8 (n = 2) and ST2 (n = 2) isolates: Whereas the former showed high-level resistance to ATM (MIC \> 32 mg/L) and were resistant to ATM-AVI (MIC, 8 mg/L), the latter showed a lower resistance level to aztreonam (MICs, 2 and 8 mg/L) and were not frankly resistant to the AZT-AVI combination (MICs, 2 and 4 mg/L, respectively). Beyond AZT-AVI, the most active antibiotics were colistin and fosfomycin (susceptibility rate of 91.4% and 80.6%, respectively). Almost all strains (97.2%) were resistant to aminoglycosides.

###### 

In Vitro Susceptibilities of 35 NDM-Producing Isolates Collected From Patients With BSI Admitted to 9 Hospitals Across Tuscany in 2018--2019

                                     MIC, mg/L          Susceptibility Rates, %         
  ---------------------------------- ------------------ ------------------------- ----- ------
  *Klebsiella pneumoniae* (n = 31)                                                      
   Ceftriaxone                       \>4                \-                        \-    100
   Ceftazidime                       \>64               \-                        \-    100
   Cefepime                          \>16               \-                        \-    100
   PIP-TAZ                           \>128/4            \-                        \-    100
   Ciprofloxacin                     \>1                \-                        \-    100
   Levofloxacin                      \>8                \-                        \-    100
   Amikacin                          \>32               \-                        \-    100
   Gentamycin                        ≤0.5 to \>8        3.2                       \-    96.8
   Meropenem                         4 to 64            \-                        3.2   96.8
   Ertapenem                         1 to \>2           \-                        \-    100
   TMP-SMX                           ≤1/19 to \>8/152   3.2                       \-    96.8
   Tigecycline                       ≤0.25 to \>4       80.6                      \-    19.4
   Colistin                          ≤0.5 to \>8        90.3                      \-    9.7
   Aztreonam                         \>32               \-                        \-    100
   Fosfomycin^a^                     4 to 64            80.6                      \-    19.4
   CLZ-TAZ                           \>64/4             \-                        \-    100
   CAZ-AVI                           \>32               \-                        \-    100
   MER-VAB                           4 to \>64          3.2                       \-    96.8
   AZT-AVI                           ≤0.25 to 1         100                       \-    \-
  *Escherichia coli* (N = 4)                                                            
   Ceftriaxone                       \>4                \-                        \-    100
   Ceftazidime                       \>64               \-                        \-    100
   Cefepime                          \>16               \-                        \-    100
   PIP-TAZ                           \>128/4            \-                        \-    100
   Ciprofloxacin                     \>1                \-                        \-    100
   Levofloxacin                      \>8                \-                        \-    100
   Amikacin                          \>32               \-                        \-    100
   Gentamycin                        \>8                \-                        \-    100
   Meropenem                         64 to \>64         \-                        \-    100
   Ertapenem                         \>2                \-                        \-    100
   TMP-SMX                           \>8/152            \-                        \-    100
   Tigecycline                       ≤0.25 to 1         75                        \-    25
   Colistin                          ≤0.5 to 1          100                       \-    \-
   Aztreonam                         2 to 32            \-                        25    75
   Fosfomycin^a^                     ≤8 to 64           75                        \-    25
   CLZ-TAZ                           \>64/4             \-                        \-    100
   CAZ-AVI                           \>32               \-                        \-    100
   MER-VAB                           64 to \>64         \-                        \-    100
   AZT-AVI                           2 to 8             \-                        50    50

Abbreviations: AZT-AVI, aztreonam-avibactam; CAZ-AVI, ceftazidime-avibactam; CLZ-TAZ, ceftolozane-tazobactam; MER-VAB, meropenem-vaborbactam; PIP-TAZ, piperacillin-tazobactam; TMP-SMX, trimethoprim-sulfamethoxazole.

^a^MIC for fosfomycin determined by agar dilution.

The clinical characteristics of the patient population and comparison between survivors and nonsurvivors are illustrated in [Table 2](#T2){ref-type="table"}. Half of the bacteremic patients were cared for in medical wards, and 47.5% had malignancy. The majority of patients (67.5%) had previous documented rectal NDM colonization. The overall 30-day mortality rate was 42.5%. Septic shock occurred in 32.5% of patients. The median age and Charlson comorbidity index score were significantly higher in nonsurviving patients than in those who survived. At the same time, primary bacteremia (unknown focus) was more common among patients who died, whereas central venous catheter (CVC)--related bacteremia was more common among survivors.

###### 

NDM-Producing *Enterobacterales* BSI: Comparison Between Survivors and Nonsurvivors (Tuscany, Italy, 2018--2019)

                                                All Patients (n = 40)   Survivors (n = 23)    Nonsurvivors (n = 17)   *P*
  --------------------------------------------- ----------------------- --------------------- ----------------------- ----------
  Age, median (IQR), y                          70.5 (55.25--77.75)     63 (48--76)           74 (67--82.5)           **.018**
  Male sex                                      28 (70)                 17 (73.9)             11 (64.7)               .530
  Ward of hospitalization                                                                                             
   Medical wards                                20 (50)                 12 (52.2)             8 (47.1)                .687
   ICU wards                                    13 (32.5)               8 (34.8)              5 (29.4)                
   Surgery                                      7 (17.5)                3 (13)                4 (23.5)                
  Comorbidities                                                                                                       
   Cardiovascular disease                       20 (50)                 9 (39.1)              11 (64.7)               .110
   Malignancy                                   19 (47.5)               9 (39.1)              10 (58.8)               .218
   COPD                                         12 (30)                 5 (21.7)              7 (41.2)                .185
   Diabetes                                     12 (30)                 8 (34.8)              4 (23.5)                .443
   Chronic renal diseases                       7 (17.5)                4 (17.4)              3 (17.6)                .983
  Charlson comorbidity index, median (IQR)      4 (2--7)                3 (0--5)              6 (3--8.5)              **.010**
  Immunosuppressive therapy,^a^ previous 30 d   15 (37.5)               7 (30.4)              8 (47.1)                .283
  Source of infection                                                                                                 
   Unknown                                      10 (25)                 3 (13)                7 (41.2)                .067
   Urinary tract                                10 (25)                 7 (30.4)              3 (17.6)                
   Intravascular device                         9 (22.5)                8 (34.8)              1 (5.9)                 
   ABSSSI                                       6 (15)                  3 (13)                3 (17.6)                
   Respiratory tract                            3 (7.5)                 2 (8.7)               1 (5.9)                 
   Intra-abdominal                              2 (5)                   0                     2 (11.8)                
  NDM-producing strain rectal colonization      27 (67.5)               17 (89.5)             10 (62.5)               .058
  Source control                                20 (50)                 12 (52.2)             8 (47.1)                .749
  SOFA score, median (IQR)                      4 (2--6)                4 (2--6)              5 (3--6.5)              .229
  Length of hospital stay, median (IQR), d      23 (13--38)             26.5 (17.25--41.75)   19 (10--33)             .187
  Septic shock                                  13 (32.5)               7 (30.4)              6 (35.3)                .746
  Antibiotic regimens                                                                                                 
   No in vitro active antibiotic therapy        14 (35)                 5 (21.7)              9 (52.9)                .054
   CAZ-AVI + ATM                                12 (30)                 10 (43.5)             2 (11.8)                
   Colistin-based regimen^b^                    9 (22.5)                4 (17.4)              5 (29.4)                
   Others^c^                                    5 (12.5)                4 (17.4)              1 (5.9)                 

Data are presented as No. (%), unless otherwise indicated. P values \< .05 (indicating statistical significance) were reported in bold.

Abbreviations: ABSSSI, acute bacterial skin and skin structures infection; ATM, aztreonam; CAZ-AVI, ceftazidime-avibactam; COPD, chronic obstructive pulmonary disease; CVC, central venous catheter; ICU, intensive care unit; IQR, interquartile range.

^a^Including steroidal and nonsteroidal immunosuppressive therapy.

^b^Colistin was used in combination with meropenem (4 cases), fosfomycin (3 cases), tigecycline (1 case), AZT + piperacillin-tazobactam (1 case).

^c^Other therapies include: 1 patient treated with fosfomycin + tigecycline + amikacin (death); 1 patient treated with meropenem + tigecycline + fosfomycin; 1 patient treated with fosfomycin alone; 1 patient treated with tigecycline + meropenem; 1 patient treated with tigecycline alone.

The most common regimens were ceftazidime-avibactam (CAZ-AVI) plus ATM (30%), followed by a colistin-based regimen (22.5%). In patients treated with CAZ-AVI plus ATM, CAZ-AVI was administered at the dosage of 2.5 g every 8 hours (in 3 patients in continuous infusion) and ATM at the dosage of 2 g every 8 hours. Dosages were eventually adjusted according to renal function. Among 26 patients (65%) receiving an antibiotic regimen showing in vitro activity against the isolated pathogen, the mortality rate was 30.8% (8/26), whereas patients who did not receive any active antibiotic therapy (n = 14, 35%) had a mortality rate of 64.3% (9/14, *P* = .041). Two patients treated with the combination of CAZ-AVI plus ATM died: 1 patient had multiple comorbidities, a severe cardiac dysfunction, and developed septic shock at time of diagnosis, while the other was an intensive care unit (ICU) patient with acute cerebral hemorrhage who was unresponsive to surgical therapy. In no cases was development of resistance to ATM-AVI detected in vivo. Time to death (IQR) was 8 (1--18.5) days in those who received in vitro active therapy, compared with 6 (1--8) days in patients who did not (*P* = .481). Cox regression analysis identified Charlson comorbidity index score (hazard ratio \[HR\], 1.221; 95% confidence interval \[CI\], 1.022--1.459; *P* = .028) and age (HR, 1.040; 95% CI, 1.012--1.079; *P* = .038) as factors independently associated with 30-day mortality.

Discussion {#s3}
==========

This is the first European report on a relatively large group of patients with bacteremia caused by NDM-producing *Enterobacterales*.

A preliminary genomic characterization of isolates revealed that the majority of episodes of BSI were caused by an NDM-1-producing strain of *K. pneumoniae* belonging to ST147. Clonal expansion, therefore, appears to be the major mechanism underlying the large outbreak of NDM-producing strains ongoing in this area, although further characterization of other isolates will be necessary to confirm the contribution of this clone and the diversity of circulating strains.

In the Tuscany cluster, BSIs caused by NDM-producing strains involved patients frequently cared for in medical wards, with multiple comorbidities and severe underlying diseases (such as cancer), and were associated with a high 30-day mortality rate. Mortality was greatly influenced by advanced age and by comorbid conditions, calculated by the Charlson comorbidity index. Moreover, mortality was significantly higher among patients not receiving an in vitro active antibiotic therapy. This latter finding underlines the importance of early detection of the molecular mechanism underlying the carbapenem resistance phenotype; it is noteworthy that some patients who died, according to previous local epidemiological data showing a predominance of KPC-producing strains, were empirically treated with CAZ-AVI alone or in combination with aminoglycosides \[[@CIT0007]\].

Data about treatment of BSI caused by NDM-producing *Enterobacterales* are very limited \[[@CIT0008], [@CIT0009]\]. Treatment regimens used in previous reports include colistin alone or in combination with aminoglycosides or meropenem, and the association of fosfomycin with meropenem \[[@CIT0010]\]. In our series, all strains were in vitro resistant to ATM, while full susceptibility was restored when combination ATM + AVI was used. The efficacy of this combination relies on the activity that the monobactam ATM typically retains against MBLs but not against ESBLs (ie, all strains in our study produced CTX-M-15). In vitro studies demonstrated a synergistic effect of the combination of CAZ-AVI plus AZT against NDM-producing isolates \[[@CIT0014], [@CIT0015]\], and a clinical study including 5 patients with bacteremia caused by NDM-producing *Enterobacterales* showed that combination therapy with CAZ-AVI plus AZT is an effective therapeutic option \[[@CIT0016]\]. Of interest, compared with other regimens, in our study surviving patients were more frequently treated with the combination of CAZ-AVI plus AZT. Although this finding was not statistically significant at Cox regression analysis, this is a potentially interesting finding that should be confirmed in larger, multicentric cohorts.

We used CAZ-AVI at a dosage of 2.5 g every 8 hours and ATM at a dosage of 2 g every 8 hours in all cases (with dose adjustment according to renal function). Recently, therapeutic drug monitoring of CAZ-AVI and ATM performed in a child with BSI caused by KPC and NDM-producing *Enterobacter* spp. showed adequate serum concentrations of the combination CAZ-AVI plus ATM, both used at a dosage of 50 mg/kg every 8 hours \[[@CIT0017]\]. If we translated this dosage in adult patients, the dose would have to be increased to 3--3.5 g every 8 hours for both ATM and CAZ-AVI. Overall, we observed a good clinical response of this combination therapy at standard dosages. Further pharmacokinetic studies are needed to assess the optimal dosage of ATM and CAZ-AVI in patients with BSI due to NDM-producing strains.

After the identification of the outbreak, several rapid actions were implemented to contain the spread of NDM-producing strains across health care facilities in the northwestern area of Tuscany. The measures included (i) mandatory screening by rapid molecular tests on admission and during hospitalization for all at-risk patients in medical wards and for all patients in the ICU, oncology, oncohematology, transplant unit, cardiac surgery, infectious diseases, acute rehabilitation; (ii) adoption of contact precautions in all cases; (iii) collection of data in a regional database and obligatory notification of all cases to a centralized laboratory; (iv) development of practical guidelines for the clinical management of NDM + cases; (v) dedicated medical and nursing staff and, in the tertiary hospital, identification of a dedicated ward for patients with colonization/infection by NDM-producing *Enterobacterales*; (vi) educational meetings for all the professionals involved \[[@CIT0018]\].

Our study has some limitations: (i) the number of BSIs is limited, but it is the largest cohort described in Europe; (ii) the multivariate analysis might be affected by the low number of cases; (iii) a high proportion of patients did not receive any active antibiotic therapy, which may have influenced the mortality rate. Nevertheless, this finding reflects clinical practice and the difficulties associated with early identification and appropriate treatment of infections caused by carbapenem-resistant *Enterobacterales* with multiple mechanisms of resistance.

In conclusion, the epidemiology of carbapenemase-producing *Enterobacterales* strains is changing over time, and new clones carrying new molecular mechanisms of resistance are emerging in some countries such as Italy. Bacteremia mediated by NDM-producing *Enterobacterales* is a highly lethal condition and requires prompt recognition and treatment. Although the combination of CAZ-AVI plus AZT appears to be a good therapeutic option in patients with NDM-producing bacteremia, the optimal regimen for the treatment of this infection is not defined and further studies are needed.
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